Current partners

PartneringVernalis has a number of potentially high-value drug development programmes in partnership at present. These include three candidates in oncology and an additional one in asthma and allergic rhinitis.

Current partnered programmes are as follows:

Item Indications Partner Status
CPI-444 Cancer Corvus Phase I/Ib data (undisclosed)
S55746 (Servier 1) Cancer Servier / Novartis Phase I data (undisclosed)
CHR-2797 (Tosedostat) Cancer CTI BioPharma Phase II Results
RPL554 Asthma, allergic rhinitis Verona Pharma Progress to nebulised delivery to treat severe COPD
V2006 (Vipadenant) Cancer Redox Therapies Partner Newsflow (undisclosed)

Latest News

FDA Issues a Complete Response Letter on CCP-08 NDA

Vernalis plc announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch